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A b s t r a c t
We h yp o th es ized  tha t heteroph il a n tib o d ies  reactive  
w ith  a n im a l p ro te in s  used  in b lo t p repara tion  caused  
n o n sp ecific  s ta in ing  (N SS) on H IV  W estern b lo t (W B)  
stud ies, cau sin g  in d e term in a te  results. We a n a lyzed  
sa m p les  sh o w in g  N S S  on  H IV  W B  using  a m u ltip lexed  
im m u n o a ssa y  to  s im u lta n eo u sly  m easure  IgG  
a n tib o d ies  to  a n im a l Ig G  (bovine, goat, sheep, m o u se ) 
a n d  b o v in e  serum  a lbum in . H etero p h il an tib o d ies  
reactive  w ith  Ig G  fro m  severa l a n im a l sp ec ie s  w ere  
d e tec ted  in 2 3  (49% ) o f  4 7  sa m p les  sh o w in g  N S S  on  
H IV  W B; 15  p o s itive  sa m p les  d em o n stra ted  an tib o d ies  
to a ll 5  an tigens. S im ila r  Ig G  heteroph il an tib o d ies  
w ere d e tec ted  in o n ly  2 (8% ) o f  2 4  con tro l sam ples. O f  
the H IV  W B  sa m p les  w ith  a p o sitive  H IV -1  enzym e-  
linked  im m u n o so rb en t a ssa y  (E L ISA ) resu lt a t the tim e  
o fW B  testing  (11/47), he teroph il a n tib o d ies  w ere fo u n d  
in 8  (73% ) o f  11. P reabsorp tion  w ith  bovine, goat, a n d  
sh eep  Ig G  rem o ved  heteroph il a n tib o d ies  d e tec ted  by  
the m u ltip lexed  a ssa y  and, in so m e  cases, e lim ina ted  
reactiv ity  in E L IS A  a n d  W B  testing . H ete ro p h il  
a n tib o d ies  are a sso c ia te d  w ith  in d e ten n in a te  H IV  
im m u n o a ssa y  resu lts a n d  are an im p o rta n t ca u se  o f  
fa ls e -p o s itiv e  H IV  E L IS A  results. M u ltip lexe d  
im m u n o a ssa ys p rov ide  a p o w e rfu l to o l f o r  screen ing  
p a tie n ts  f o r  he teroph il a n tib o d ies  a n d  reso lving  
p o ss ib le  fa ls e -p o s itiv e  results.
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Heterophil antibodies are widely recognized as a cause 
of interference in immunoassays. Heterophil antibodies are 
thought to demonstrate multispecificity by having multiple 
binding sites or by having a single binding site that can 
recognize a number of antigens with similar structures . 1 
Heterophil antibodies can create a false-positive result in an 
immunoassay by binding to the capture and signal antibodies 
in the assay and mimicking the behavior of the analyte of 
interest. Heterophil interference has been observed in many 
immunoassays, including creatine kinase M B ,2 human chori­
onic gonadotropin,3 C.A-125,4 thyroid stimulating hormone,5 
and others, but has not been well characterized in HIV 
immunoassays.6
False-positive HIV enzyme-linked immunosorbent assay 
(ELISA) results can occur with serious medical, social, and 
legal consequences,7 and false-positive results are thought to 
account for as many as 4.6% of positive Western blots in a 
low-risk screening setting.8 The HIV Western blot can yield 
indeterminate results because of nonviral bands or cross­
reacting autoantibodies.9' 10 Nonspecific staining (NSS) is not 
addressed specifically in the criteria for interpreting HIV 
Western blot assays. 11 Since NSS can obscure a viral band on 
the blot, many laboratories will not interpret a blot with NSS 
as negative but instead report a result of indeterminate with a 
recom m endation for retesting. We hypothesized that the 
majority of NSS observed on HIV Western blots was due to 
heterophil antibodies, since anim al proteins, including 
immunoglobulins, are used in the manufacture of the blots. 
Furthermore, any sample with heterophil antibodies that 
caused NSS on a Western blot also might show a false-posi­
tive result on an ELISA.
To detect heterophil antibodies in samples showing NSS 
that were potentially reactive with many different antigens,
© American Society of Clinical Pathologists
Immunopathology / Originai Artici f.
we used microsphere-based multiplexed immunoassays on 
the Luminex platform (Luminex, Austin, TX). The Luminex 
analyzer performs flow cytometric analysis of microsphere- 
based immunoassays with simultaneous measurement of 
m ultiple analy tes . 12 We used a panel o f anim al serum  
proteins commonly used in immunoassays, including poly­
clonal bovine, goat, sheep, and mouse IgG and bovine serum 
albumin (BSA). In the present study, we screened for a 
subset of heterophil antibodies likely to cause interference in 
immunoassays by simultaneously measuring human IgG 
reactive with these antigens. We report that human serum 
samples producing NSS on HIV Western blots often contain 
heterophil IgG antibodies reacting with a variety of serum 
proteins from other animal phyla.
M aterials and Methods
Patients and Serum Samples
During a 5-month period (July 1, 1999-November 30, 
1999), 2,518 consecutive samples were submitted to ARUP 
Laboratories, Salt Lake City, UT, for HIV Western blot 
testing. Samples were tested according to the manufacturer's 
protocol (Sanofi D iagnostics Pasteur, Redm ond, WA). 
According to the manufacturer's recommendations, “Strips 
which are obscured by the development of dark blotches or 
marks should not be interpreted.” 13 All blots showing NSS, 
as determined by the technologist at the time of testing, were 
given an interpretation of indeterminate for HIV-1 infection 
in the final laboratory report. Serum from any blot that 
showed NSS was selected for heterophil antibody analysis. 
A ll samples were tested sim ultaneously with an HIV-1 
ELISA assay (Organon Teknika, Durham, NC). Seram was 
stored at -20°C. When available, patient information was 
obtained from the submitting physician.
Control Group
The control group was 24 serum samples from random 
blood donors. None of these samples were positive for 
hepatitis B core antibodies, hepatitis B surface antigen, 
hepatitis C. antibodies, antibodies to human lymphotropic 
virus I or II, antibodies to HIV-1, or p24 antigen.
Multiplex Heterophil Immunoassay
M icrosphere Preparation
BSA and bovine, goat, sheep, mouse, and human IgG 
(Sigma Chem ical, St Louis, MO) were conjugated to 6  
unique fluorescently labeled microsphere sets (Luminex) 
with a carbodiimide coupling method. Two hundred micro­
liters of 1.25 x  1011 microspheres per liter stock solution (2.5 
x  106 microspheres) was activated in 100 ^L of a 0.1-mol/L
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concentration of sodium phosphate buffer containing 500 ng 
of N-hydroxysulfosuccinimide sodium. Microspheres were 
washed twice with 250 ^L of phosphate-buffered saline 
(PBS) (pH 7.3), w ith centrifugation at 10,000# for 60 
seconds, to harvest the microspheres. Activated, washed 
microspheres were suspended in 250 ^L of a 50 |ag/mL solu­
tion of BSA or animal IgG in PBS. After 1 hour, coated 
microspheres were washed twice with 250 ^L of PBS with 
0.2 mL/L of polysorbate 20, pH 7.3 (PBS/polysorbate), 
suspended in 1 mL of PBS/polysorbate, and enumerated on a 
hemocytometer. The final concentrations of the individual 
microspheres ranged from 1.1 to 1.7 X 103/mL. A solution of 
all 6  unique microspheres in PBS/polysorbate was made, 
with each microsphere at a concentration of 1 x  1 0 5 micro­
spheres per milliliter.
M ultiplexed A ssay fo r  H eterophil Antibodies
For this assay, 50 ^L of a 1:50 dilution of patient serum 
in PBS and 50 ^L of the 6 -microsphere solution were mixed 
in a filter-bottomed microtiter well and incubated for 2 0  
minutes. The microspheres were washed 3 times with 250 
HL of PBS/polysorbate. Then, 100 ^L of a 0.04-|ag/mL solu­
tion of biotinylated goat antihuman IgG (Pierce Chemicals, 
Rockford, IL) was added to the microspheres and incubated 
for 20 minutes, and the microspheres were washed 3 times 
with 250 (iL of PBS/polysorbate. Next, 100 |iL of a 10- 
Hg/mL solution of streptavidin-phycoerythrin conjugate 
(Molecular Probes, Eugene, OR) was added to the micro­
spheres and incubated for 1 0  minutes, and the microspheres 
were washed 3 times with 250 ^L of PBS/polysorbate. The 
microspheres were resuspended in 200 ^L of PBS/polysor­
bate and assayed with the Luminex system.
Preabsorption o f  H eterophil Antibodies
For preabsorption, 5 mg/mL solutions of bovine, goat, 
and sheep IgG in PBS were used for binding to the coupling 
gel (product number 20501, Pierce Chemicals) according to 
the manufacturer's instructions. The gel with bound animal 
IgG was stored as a 50% slurry in PBS/polysorbate; 100 ^L 
of each of the 3 gel slurries was added to 5 ^L of patient 
serum and mixed. The gel mixture was incubated at room 
temperature for 60 minutes followed by centrifugation at 
10,000# for 3 minutes. The supernatant was diluted to 1:50 
in PBS and submitted for multiplex analysis. For preabsorp­
tion in the HIV-1 ELISA and Western blot (Sanofi Diagnos­
tics Pasteur) assays, the supernatant was diluted in the appro­
priate specimen diluent and analyzed in the usual manner.
Results
From July 1, 1999, to November 30, 1999, 2,518 HIV 
Western blots were performed. Of these, 47 (1.9%) showed
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NSS. Examples of blots showing NSS are shown in llmage 
II. NSS varied from strong, dark, diffuse staining to light, 
blotchy staining. However, any staining that potentially 
could obscure the identification of a viral band was recorded 
as NSS, and the result was interpreted as indeterminate for 
HIV infection.
Patient inform ation was available for 25 of the 47 
samples showing NSS. One patient was a homosexual male, 
but no other patients had known risk factors for HIV infec­
tion. In many cases, testing was perform ed for routine 
prenatal care, blood donation, or evaluation for dialysis or 
transplantation or because a health care worker was exposed 
to the patient’s blood. Six months after the time of Western 
blot testing, none of the patients for whom information was 
available were known to be HIV positive.
Of the 47 samples, 11 (23%) had a positive HIV-1 
ELISA result, and results for 36 (77%) were negative. 
Presumably all of these patients had a positive HIV ELISA 
result in another laboratory, since samples were sent to our 
laboratory for confirmatory Western blot testing only. Each 
of the 11 samples with a positive HIV-1 ELISA result in our 
laboratory was only slightly above the positive cutoff for the 
assay. Most true-positive samples have signal/cutoff ratios 
greater than 5.0, while the ELISA-positive samples in our 
study had signal/cutoff ratios ranging from 1.02 to 2.98.
IFigure II shows the results of the multiplex analysis for 
heterophil antibodies in 2  human serum samples demon­
strating NSS in the HIV Western blot. Reactivity with cow, 
goat, sheep, and mouse IgG and BSA is shown. Each vertical 
bar represents the average amount of fluorescence measured 
on the microspheres labeled with a given antigen, corre­
sponding to the amount of IgG antibody present. A separate 
microsphere coated with human IgG used to demonstrate 
adequate labeling with the antihuman secondaiy antibody is
llmage II Examples of nonspecific staining on HIV Western 
blots. Blots 1 and 8 , negative controls; blots 2 and 3, positive 
controls; blots 4-7, nonspecific staining. Blots 4-7 show 
various levels of diffuse darkening in comparison with blots 1 
and 8  (negative controls), gp, glycoprotein.
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not shown. The positive cutoff for each antigen was the mean 
reactivity of the blood bank population for that antigen plus
2.5 SD. The positive cutoff mean fluorescence intensities 
were as follows: cow IgG, 6,580; goat IgG, 7,450; sheep 
IgG, 7,770; mouse IgG, 1,830; and BSA, 2,150.
Multiplex analysis of control blood bank samples for 
heterophil antibodies indicated 2 (8 %) of 24 had heterophil 
antibodies. These results are shown in IFigure 21. In the 
samples that contained heterophil antibodies, one contained 
antibodies to all 5 heterophil antigens, while the other had 
antibodies to only mouse IgG.
As shown in Figure 2, multiplex analysis of the samples 
showing NSS on HIV Western blot indicated that 23 (49%) 
of 47 had heterophil antibodies directed against 1 or more 
animal species IgG. This is significantly higher than the 
results for the control population (P < .001). Fifteen samples 
contained antibodies reactive with all 5 antigens, 1 sample 
showed reactivity to 4 antigens, 3 samples showed reactivity 
to 3 antigens, 1 sample showed antibodies to 2 antigens, and
3 sam ples had antibodies to only 1 antigen. For each 
heterophil antigen, the results were as follows: 2 0  samples 
had antibodies to mouse IgG, 19 samples contained anti­
bodies to bovine IgG, 19 samples were positive for anti­
bodies to sheep IgG, 18 samples had antibodies to goat IgG, 
and 18 samples contained antibodies to BSA.
Of the 11 samples that were positive in our laboratory 
by HIV-1 ELISA, 8  (73%) contained heterophil antibodies. 
Of the 36 samples that were negative in our laboratory by 
HIV-1 ELISA, 14 (39%) had heterophil antibodies by our 
analysis. These rates are significantly different (P < .05).
We next attempted to remove the heterophil antibodies 
from the patient serum by preabsorbing the serum with cow, 
goat, or sheep IgG bound to a gel solid phase. Antibodies 
with these specificities were chosen for preabsorption 
because they were present in the highest titers in the multi­
plex analysis. Preabsorption was performed on a subset of 
samples that had shown a positive result on HIV-1 ELISA. 
Preabsorbed patient serum samples showed marked reduc­
tion in the levels of heterophil antibodies, as shown in ITable 
II. In almost all cases, after preabsorption with bovine, goat, 
and sheep IgG, heterophil antibody levels for all 5 heterophil 
antigens were below  the positive cutoff. One sam ple 
continued to show antibodies to mouse IgG above the posi­
tive cutoff after preabsorption.
Preabsorbed serum samples also were retested using the 
HIV-1 ELISA and HIV Western blot. Positive and negative 
control samples also were preabsorbed and reacted appropri­
ately following preabsorption. Of 9 samples initially positive 
by HIV-1 ELISA, 5 were negative after preabsorption and 4 
remained positive. The samples that remained positive had 
shown antibodies to all 5 antigens; however, after absorption 
only 1 sample showed remaining heterophil antibodies that
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IFigure II Two specimens analyzed for immunoreactivity to 5 
antigens, represented by 5 vertical bars. Increasing mean 
fluorescence intensity represents increasing patient antibody 
reacting with a particular antigen. BSA, bovine serum 
albumin.
Antibovine IgG Antigoat IgG Antisheep IgG Antimouse IgG Anti-BSA
IFigure 21 Multiplex analysis for heterophil antibodies in the 
blood bank control population and in samples showing 
nonspecific staining on HIV Western blot (WB). The error 
bars for the control population represent the mean + 2.5 SD. 
Of 47 samples, 23 (49%) with nonspecific staining showed 
significant levels of heterophil antibodies to 1 or more 
antigens, while only 2 (8 %) of 24 of the control population 
had heterophil antibodies.
had specificity for only mouse IgG. Presumably, remaining 
interfering antibodies had different specificities.
Five samples were retested by HIV Western blot after 
preabsorption, and 3 of these were negative with no NSS. 
Two samples continued to show NSS. These samples did not 
show heterophil antibodies on multiplex analysis after preab­
sorption, so that any antibodies continuing to cause interfer­
ence presumably had different specificities.
Discussion
In d e te rm in a te  and fa lse -p o sitiv e  re su lts  in  HIV 
immunoassays are a substantial problem for physicians, 
public health authorities, and, especially, patients; recognition
of false-positive results potentially can alleviate much confu­
sion and anxiety. Heterophil antibodies are common in the 
general population14' 16 and frequently cause interference 
and fa lse-positive  resu lts  in  many types of im m uno­
assays. 2"5'7' 17"19 Heterophil antibodies have not previously 
been shown definitively to interfere in HIV immunoassays.6 
With a unique multiplexed immunoassay, we have demon­
strated that heterophil antibodies can cause false-positive 
HIV ELISA results in cases in which there are no known risk 
factors and c lin ica l susp ic ion  is low. In many cases, 
heterophil antibodies cause additional problems in HIV 
testing because they interfere in the confirmatory Western 
blot test, resulting in NSS and an interpretation of an indeter­
minate result for HIV infection.
ITable II
Heterophil Antibody Content and HIV-1 ELISA and HIV WB Results Before and After Antibody Preabsorption
Sam ple
A ntibovinc IgG* A ntigoat IgG* A ntisheep IgG* HIV-1 ELISA S ignal/C utoff1 HIV-1 WB
Before A fter Before A fter Before A fter Before A fter Before A fter
1 16,806 2,262 13,926 837 14,636 1,861 2.33 (+) 1.74 (+) _ _
2 4,479 1,303 5,012 294 7,371 836 2.13 (+) 0.35 H NSS Negative
3 17,433 3,554 18,895 795 18,771 2,097 1.74 (+) 1.51 (+) NSS NSS
4 6,180 1,741 7,972 435 9,681 2,941 1.03 (+) 0.44 H NSS Negative
5 18,949 2,608 21,532 1,079 2 0 ,8 8 8 1,793 2.98 (+) 1.48 (+) NSS NSS
6 14,704 2,829 18,960 1,403 12,389 3,178 1.45 (+) 0.78 (-) NSS Negative
7 17,845 2,349 17,277 834 15,960 1,895 1.58 (+) 0.60 H — —
8 14,924 1,973 15,405 482 16,933 1,521 1.05 (+) 1.43 (+) — —
9 9,569 2,078 5,853 462 6,617 1,177 1.02 (+) 0.48 H — —
ELISA, enzyme-linked immunosorbent assay; NSS, nonspecific staining; WB, Western blot. 
* Measured as mean fluorescence intensity.
T A signal/cutoff ratio greater than 1.0 is a positive result.
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We detected and characterized heterophil antibodies by 
multiplexed microsphere-based immunoassays, which allow 
simultaneous measurement of immunoreactivity to multiple 
antigens. Because heterophil antibodies characteristically 
react with immunoglobulins from multiple species,20 multi­
plex analysis is ideal for their detection. In our analysis we 
used polyclonal bovine, goat, sheep, and mouse IgG and 
BSA, because these are common components of commercial 
immunoassays. Most positive samples (16/23 [70%]) in our 
analysis showed antibodies to at least 4 of these antigens. 
The specific animal proteins used in the commercial HIV 
immunoassay kits are not indicated by the manufacturer, 
although the specim en diluents are reported to contain 
bovine, caprine, and milk proteins13-21; presumably these are 
selected to match the proteins present on the solid phase of 
the assay.
Previous reports o f heterophil antibodies have not 
commonly measured immunoreactivity to multiple species’ 
immunoglobulins, 14-15 and whether reactivity to the combina­
tion of heterophil antigens we tested is characteristic is not 
clear. One possible explanation is that all of these species 
have immunoglobulins that are antigenically similar. This 
could explain why most patients showed antibodies to 
m ultiple species and preabsorption with only 1 antigen 
reduced  the level o f an tibod ies to a ll o f the an tigens 
measured. To further characterize heterophil antibodies in 
future studies, multiplex testing could examine immunoreac­
tivity for many more antigens and also could include specific 
immunogens such as monoclonal mouse therapeutic agents or 
specific monoclonal antibodies used as radiolabeling agents. 
Such a panel could contain the immunoglobulins or proteins 
most frequently used in immunoassays and the monoclonal 
therapeutic agents most commonly used in humans.
If the use of multiplexed m icrosphere-based assays 
becomes more common and panels of tests are performed on 
this platform, a set of heterophil antigen microspheres could 
be added to the panel to monitor heterophil antibody activity 
in all samples tested. For example, if a panel included 
microspheres to detect antibodies to HIV, hepatitis B anti­
gens, and hepatitis C, additional microspheres with a set of 
heterophil antigens could simultaneously detect heterophil 
antibodies and raise suspicion for interference in other 
immunoassays.
Once heterophil antibodies were identified in a patient 
with a suspected interference on HIV immunoassays, in 
some cases we were able to remove the antibodies by incu­
bation with heterophil antigens. In our analysis, more than 
half o f false-positive HIV-1 ELISA results and NSS on 
Western blot were removed by incubation with polyclonal 
bovine, goat, and sheep IgG to remove heterophil antibodies. 
O ther investiga to rs have also  been able to e lim inate  
heterophil antibody activity by preabsorption,2-22-23 although
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som e stud ies used an im al serum  w hile o thers used 
immunoglobulins only or F(ab') fragments.
In our study, preabsorption reduced antibody levels to 
those of the control population except for 1 sample that 
continued to show antibodies reactive with mouse IgG. The 
continued false-positive result of some samples after preab­
sorption was probably due to antibodies with other specifici­
ties that had not been removed.
M ultiplex m icrosphere-based im munoassays are an 
excellent means for detecting heterophil antibodies. By using 
this technology, we have shown heterophil antibodies can be 
an important cause of false-positive HIV immunoassay 
results, and heterophil interference should be suspected in 
any case in which the HIV immunoassay results are at odds 
with the clinical situation. Additional studies to further char­
acterize the specificity of heterophil antibodies, to detect 
heterophil interference in other settings, and to remove 
heterophil antibodies from clinical samples will be necessary 
to determine the scope of the problem and effective means of 
controlling it.
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